Torrent Pharmaceuticals has entered into a strategic alliance with Boehringer Ingelheim India to co-market Cospiaq, which is useful for improving glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus. 2 and established cardiovascular disease.
Torrent Pharmaceuticals has entered into a strategic alliance with Boehringer Ingelheim India to jointly market Cospiaq (Empagliflozin), Cospiaq MetTM (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin) in India, the pharmaceutical companies said in a joint statement on Wednesday.
Empagliflozin is useful for improving glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
Additionally, empagliflozin is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.
According to the International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (age group 20-79 years) as of 2021. This is expected to increase to nearly 125 million patients by 2045. According to AWACS MAT, Oct 2022 data, the Indian diabetes drug market is valued at INR 16,516 crore, growing at 8.6% CAGR over the last 4 years.
The SGLT-2 inhibitor market is valued at Rs 1,927 crore and SGLT-2 inhibitors are growing faster than the diabetes market with a CAGR of 33% over the same time period.
Aman Mehta, Director of Torrent Pharmaceuticals, said, "Torrent is pleased to enter into a strategic partnership with Boehringer Ingelheim India to address the dual challenges of type 2 diabetes and heart failure (both preserved and reduced ejection fractions) in India."
โOur collaboration with Torrent reaffirms our commitment to enable better access to innovative medicine in India. We believe that bringing the healthcare ecosystem together is key to addressing the unmet needs of patients,โ said Vani Manja, CEO of Boehringer Ingelheim India.
